A double-blind study to assess the efficacy and safety of clazosentan in reducing cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage treated by endovascular coiling

The incidence of Morbidity/Mortality events was significantly decreased in the clazosentan 10 mg/h group compared with the placebo group. The incidence of adverse events in the clazosentan 10 mg/h group differed from the placebo group in terms of fluid retention events and anemia, but there were no new safety concerns.